Myeloablation by intravenous busulfan and hematopoietic reconstitution with autologous marrow in a canine model

Biology of Blood and Marrow Transplantation

Volumn 5, Issue 5, 1999, Pages 316-321

  Deeg, H Joachim ^a,c   Schuler, Ulrich S ^b   Shulman, Howard ^a   Ehrsam, Michael ^b   Renner, Ulf ^b   Yu, Cong ^a   Storb, Rainer ^a   Ehninger, Gerbard ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Autologous stem cell transplantation; Canine model; Intravenous busulfan; Myeloablative dose

Indexed keywords

BUSULFAN; MYELOABLATIVE AGENT;

ANIMAL; ARTICLE; AUTOTRANSPLANTATION; BIOLOGICAL MODEL; BLOOD; BLOOD CELL COUNT; BONE MARROW TRANSPLANTATION; DOG; DOSE RESPONSE; DRUG EFFECT; HEMATOPOIESIS; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; NEUTROPHIL; THROMBOCYTE COUNT;

ANIMALS; BLOOD CELL COUNT; BONE MARROW TRANSPLANTATION; BUSULFAN; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOPOIESIS; INJECTIONS, INTRAVENOUS; LEUKOCYTE COUNT; MODELS, BIOLOGICAL; MYELOABLATIVE AGONISTS; NEUTROPHILS; PLATELET COUNT; TRANSPLANTATION, AUTOLOGOUS;

EID: 0032620731     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(99)70007-8     Document Type: Article

References (29)

1. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB, Braine HG, Burns WH, Elfenbein GJ, Kaizer H, Mellits D, Sensenbrenner LL, Stuart RK, Yeager AM: Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 309:1347, 1983.
2. Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI, Soll E, Anasetti C, Bowden R, Bryant E, Chauncey T, Deeg HJ, Doney KC, Flowers M, Gooley T, Hansen JA, Martin PJ, McDonald GB, Nash R, Petersdorf EW, Sanders JE, Schoch G, Stewart P, Storb R, Sullivan KM, Thomas ED, Witherspoon RP, Appelbaum FR: Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 89:3055, 1997.
3. Clift RA, Buckner CD, Thomas ED, Bensinger WI, Bowden R, Bryant E, Deeg HJ, Doney KC, Fisher LD, Hansen JA, Martin P, McDonald GB, Sanders JE, Schach G, Singer J, Storb R, Sullivan KM, Witherspoon RP, Apfelbaum FR: Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 84:2036, 1994.
4. Blaise D, Maraninchi D, Archimbaud E, Reiffers J, Devergie A, Jouet JP, Milpied N, Attal M, Michallet M, Ifrah N, Kuentz M, Dauriac C, Bordigoni P, Gratecos N, Guilhot F, Guyotat D, Gouvernet J, Gluckman E: Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the Groupe d'Etudes de la Greffe de Moelle Osseuse. Blood 79:2578, 1992.
5. Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE, York RC, Lin LS, Devine SM, Geller RB, Heffner LT, Hillyer CD, Holland HK, Winton EF, Saral R: Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 17:225, 1996.
6. Ljungman P, Hassan M, Bekassy AN, Ringden O, Oberg G: Busulfan concentration in relation to permanent alopecia in recipients of bone marrow transplants. Bone Marrow Transplant 15:869, 1995.
7. Hassan M, Oberg G, Bjorkholm M, Wallin I, Lindgren M: Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol 33:181, 1993.
8. Slattery JT, Kalhorn TF, McDonald GB, Lambert K, Buckner CD, Bensinger WI, Anasetti C, Appelbaum FR: Conditioning regimendependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol 14:1484, 1996.
9. Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen T-L, Saral R, Santos GW, Colvin OM: Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 25:55, 1989.
10. Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP, Anasetti C, Bensinger WI, Fisher LD, Appelbaum FR, Hansen JA: Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 16:31, 1995.
11. Hassan M, Oberg G, Bekassy AM, Aschan J, Ehrsson H, Ljungman P, Lonnerholm G, Smedmyr B, Taube A, Wallin I, Simonsson B: Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol 28:130, 1991.
12. Hassan M, Ljungman P, Bolme P, Ringden O, Syruckova Z, Bekassy A, Stary J, Wallin I, Kallberg N: Busulfan bioavailability. Blood 84:2144, 1994.
13. Hassan M, Oberg G, Ehrsson H: Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol 36:525, 1989.
14. Vassal G, Koscielny S, Challine D, Valteau-Couanet D, Boland I, Deroussent A, Lemerle J, Gouyette A, Hartmann O: Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. Cancer Chemother Pharmacol 37:247, 1996.
15. Grochow LB: Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 20:18, 1993.
16. Schuler U, Schroer S, Kuhnle A, Blanz J, Mewes K, Kumbier I, Proksch B, Zeller KP, Ehninger G: Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplant 14:759, 1994.
17. Yeager AM, Wagner JEJ, Graham ML, Jones RJ, Santos GW, Grochow LB: Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. Blood 80:2425, 1992.
18. Vassal G, Challine D, Koscielny S, Hartmann O, Deroussent A, Boland I, Valteau-Couanet D, Lemerle J, Levi F, Gouyette A: Chronopharmacology of high-dose busulfan in children. Cancer Res 53:1534, 1993.
19. Ehninger G, Schuler U, Renner U, Ehrsam M, Zeller KP, Blanz J, Storb R, Deeg HJ: Use of a water-soluble busulfan formulation: pharmacokinetic studies in a canine model. Blood 85:3247, 1995.
20. Schuler US, Ehrsam M, Schneider A, Schmidt H, Deeg J, Ehninger G: Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation. Bone Marrow Transplant 22:241, 1998.
21. Hassan M, Hassan Z, Nilsson C, Rehim MA, Kumlien S, Elfsson B, Kallberg N: Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration. Cancer Chemother Pharmacol 42:471, 1998.
22. Bhagwatwar HP, Phadungpojna S, Chow DS, Andersson BS: Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Cancer Chemother Pharmacol 37:401, 1996.
23. Vaughan WP, Cagnoni P, Fernandez H, Hu W, Kashyap A, Gain V, Wingard J, Tarantolo S, Andersson BS: Pharmacokinetics of intravenous busulfan in hematopoietic stem cell transplantation (HSCT) [Abstract]. ASBMT Abstract Book 22:78, 1999.
24. Deeg HJ, Storb R: Bone marrow transplantation in dogs. In: L Makowka, DV Cramer, LG Podesta (eds) Handbook of Animal Models in Transplantation Research, Boca Raton, FL: CRC Press, 255, 1994.
25. Blanz J, Rosenfeld C, Proksch B, Ehninger G, Zeller KP: Quantitation of busulfan in plasma by high-performance liquid chromatography using postcolumn photolysis. J Chromatogr 532:429, 1990.
26. Kolb HJ, Storb R, Weiden PL, Ochs HD, Kolb H, Graham TC, Floersheim GL, Thomas ED: Immunologic, toxicologic and marrow transplantation studies in dogs given dimethyl myleran. Biomedicine 20:341, 1974.
27. Shaw PJ, Scharping CE, Brian RJ, Earl JW: Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia. Blood 84:2357, 1994.
28. Storb R, Weiden PL, Graham TC, Lerner KG, Nelson N, Thomas ED: Hemopoietic grafts between DLA-identical canine littermates following dimethyl myleran. Evidence for resistance to grafts not associated with DLA and abrogated by antithymocyte serum. Transplantation 24:349, 1977.
29. Deeg HJ, Storb R, Weiden PL, Schumacher D, Shuhman H, Graham T, Thomas ED: High-dose total-body irradiation and autologous marrow reconstitution in dogs: dose-rate-related acute toxicity and fractionation-dependent long-term survival. Radiat Res 88:385, 1981.